Michael Gibson, MD
PeerEarly aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Michael Koren, MD
PeerNo effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Javed Butler, MD
PeerDmitry M. Yaranov, MD
PeerImproving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD, FASN
PeerLearning About the New Definition of MASLD